Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2095)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (83)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4630)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)
    Meeting Abstract

    Sartor, O.; Castellano Gauna, D. E.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N. N.; Crosby, M.; Piulats Rodriguez, J. M.; Flechon, A.; Wei, X. X.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Spicer, J. D.; Gao, S.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C.; Majem, M.; Eigendorff, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H. H. F.; Goto, K.; Solomon, B. J.; Park, K.; Pérol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Meeting Abstract

    Ho, A. L.; Adkins, D. R.; Hanna, G. J.; Bruce, J.; Ahn, M. J.; Iglesias Docampo, L.; Kang, H.; Wong, D. J.; Psyrri, A.; Gillison, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
    Meeting Abstract

    Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save